Persistence of antibodies at 5-6 years of age for children who had received a primary series vaccination with a pentavalent whole-cell pertussis vaccine and a first booster with a pentavalent acellular pertussis vaccine: Immunogenicity and tolerance of second booster with a tetravalent acellular vaccine at 5-6 years of age

Vaccine

Volumn 22, Issue 11-12, 2004, Pages 1406-1414

  Langue, Jacques ^a   Matisse, Noëlle ^a   Pacoret, Patrick ^a   Undreiner, François ^a   Boisnard, Florence ^b   Soubeyrand, Benoît ^b  

^a L'Espace Médical ^*  (France)

^b SANOFI PASTEUR   (France)

Author keywords

1 dil; Acellular pertussis; AcP; D; Diphtheria; Diphtheria, tetanus, acellular pertussis, inactivated polio vaccine, H. influenzaetype b; Diphtheria, tetanus, whole cell pertussis, inactivated polio vaccine, H. influenzaetype b; DTacP IPV Hib; DTwcP IPV Hib

Indexed keywords

ACELLULAR VACCINE; ANTIBODY; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS VACCINE; DIPHTHERIA PERTUSSIS TETANUS POLIOMYELITIS HEMOPHILUS INFLUENZAE TYPE B VACCINE; DIPHTHERIA VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEMAGGLUTININ; PENTACOQ; PENTAVAC; PERTUSSIS TOXIN; PERTUSSIS VACCINE; POLIOMYELITIS VACCINE; POLYRIBOSYLRIBITOL PHOSPHATE; RIBITOL; TETANUS TOXOID; TETRAVAC; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ANOREXIA; ANTIBODY TITER; ARTHRALGIA; ARTICLE; BORDETELLA PERTUSSIS; CLINICAL TRIAL; CLOSTRIDIUM TETANI; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DIPHTHERIA; DROWSINESS; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; ERYTHEMA; FEMALE; FEVER; HEADACHE; HUMAN; HYPOTHERMIA; IMMUNOGENICITY; INFLUENZA; INJECTION PAIN; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; PAIN; PERTUSSIS; PHARYNGITIS; PHASE 3 CLINICAL TRIAL; POLIOMYELITIS; POLIOMYELITIS VIRUS; PRESCHOOL CHILD; PRIORITY JOURNAL; RHINITIS; SIDE EFFECT; SKIN INDURATION; SLEEP DISORDER; TETANUS; VACCINATION; VOMITING;

ANTIBODIES, BACTERIAL; ANTIBODY FORMATION; CHILD; CHILD, PRESCHOOL; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; FEMALE; FRANCE; HUMANS; IMMUNIZATION, SECONDARY; IMMUNOENZYME TECHNIQUES; IMMUNOLOGIC MEMORY; INFANT; MALE; PERTUSSIS VACCINE; POLIOVIRUS VACCINES; VACCINES, COMBINED;

EID: 1842509144     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2003.10.026     Document Type: Article

References (31)

1. Baron S., Grimprel E. Epidemiological estimate of anti-pertussis vaccination efficacy during epidemics in community [Estimation épidémiologique de l'efficacité de la vaccination anticoquelucheuse au cours d'épidémies en collectivité]. Arch. Pédiatr. 4:1997;744-750.
2. Avis du conseil supérieur d'hygiène publique de France du 13 mars 1998. Calendrier vaccinal 1998. Bulletin Epidémiologique Hebdomadaire 1998; No. 15.
3. La Vaccination contre la Coqueluche des nourrissons. Avis du Conseil Supérieur d'Hygiène Publique de France. Bulletin Epidémiologique Hebdomadaire 2001; No. 19.
4. Langue J, David T, Roussel F, Pines E, Hoffenbach A. Safety and immunogenicity of DTaP-IPV and Act-Hib(tm) vaccines administered either combined or separately to infants at 2, 3 and 4 months of age. In: 15th Annual Meeting of European Society for Paediatric Infectious Diseases in Paris; 1997 [Abstract].
5. Mallet E, Hoffenbach A, Pines E, Salomon H. Immunogenicity of the fourth dose of a combined DTaP-IPV/Act-Hib(tm) vaccine administered at 15 months of age to children primed either at 2, 3, and 4 or at 2, 4, and 6 months of age. In: 15th Annual Meeting of European Society for Paediatric Infectious Diseases in Paris; 1997 [Abstract].
6. Carlsson R.M., Claesson A., Fagerlund E., Knutsson N., Lundin C. Antibody persistence in five-year-old children who received a pentavalent combination vaccine in infancy. Pediatr. Infect. Dis. J. 21:2002;535-541.
7. David T, Cadoz M, Gobert T, et al. Comparison to a DTP-IPV with a whole-cell pertussis component in infants. In: 31st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago; 29 September to 2 October 1991 [Abstract].
8. Simondon F., Yam A., Gagnepain J.Y., Wassilak S., Danve B., Cadoz M. Comparative safety and immunogenicity of an acellular versus whole-cell pertussis component of diphtheria-tetanus-pertussis vaccines in senegalese infants. Eur. J. Microbiol. Infect. Dis. 15:1996;927-932.
9. Edwards K.M., Meade B.D., Decker M.D.et al. Comparison of 13 acellular pertussis vaccines: overview and serologic response. Pediatrics. 96:1995;548-557.
10. Auerbach B.S., Wilson M.E., Lake A.M.et al. Dose-response to acellular pertussis vaccine and comparison with whole cell pertussis vaccine at 15-24 months and 4-6 years of age. Vaccine. 10:1992;14-20.
11. Miller E, Miller DL, Ashworth LAE, Waight PA, Harbert K. Comparison of antibody responses and symptoms following primary immunisation with British whole-cell and three acellular DTP Vaccines. In: Manclark CR, editor. Proceedings of the Sixth International Symposium on Pertussis, Bethesda, Maryland: (FDA) 90-1164; 1990. p. 303-10.
12. Edwards K.M., Decker M.D., Bradley R.B., Taylor J.C., Hager C.C. Booster response to acellular pertussis vaccine in children primed with acellular or whole-cell vaccines. Pediatr. Infect. Dis. J. 10:1991;315-318.
13. Edwards K.M., Bradley R.B., Decker M.D., Palmer P.S., Van Savage J., Taylor J.et al. Evaluation of a new highly purified pertussis vaccine in infants and children. J. Infect. Dis. 160:1989;832-837.
14. Edwards K.M. Acellular pertussis vaccines-a solution to the pertussis problem? J. Infect. Dis. 168:1993;15-20.
15. Decker M.D., Edwards K.M., Steinhoff M.C., Rennels M.B., Pichichero M.E., Englund J.A.et al. Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics. 96:1995;557-566.
16. He Q., Viljanen M.K., Nikkari S., Lyytikäinen R., Mertsola J. Outcomes of Bordetella pertussis infection in different age groups of an immunized population. J. Infect. Dis. 170:1994;873-877.
17. Esposito S., Agliardi T., Giammanco A., Faldella G., Cascio A., Bosis S.et al. Long-term pertussis-specific immunity after primary vaccination with a combined diphtheria, tetanus, tricomponent acellular pertussis, and hepatitis B vaccine in comparison with that after natural infection. Infect. Immun. 69:2001;4516-4520.
18. Camargo M.E., Silveria L., Furuta J.A., Oliveria E.P., Germek O.A. Immunoenzymatic assay of anti-diphteria toxin antributes in human serum. J Clin Microbiol. 20:1984;772-774.
19. Melville-Smith M.E., Seagroatt V.A., Watkins J.T. A comparison of enzyme linked immunosorbent assay (ELISA) with the toxin neutralisation test in mice as a method for the estimation of tetanus antitoxin in human sera. J Biol Stand. 11:1983;137-144.
20. Manclark CR, Meade BD, Burstyn DB. Serological response to bordetella pertusis. In: Rose NR, Friedman H, Fahey JL, editors. Manual of clinical laboratory immunology. 3rd ed. Washington, DC: American Society for Microbiological; 1986. p. 388-94.
21. Grenier B., Hamza B., Biron G., Xueref C., Viarme F., Roumianteff M. Seroimmunity following vaccination in infants by an inactivated poliovirus vaccine prepared on Vero cells. Rev. infect. Dis. 6(Suppl. 2):1984;545-547.
22. Farr R.S. A quantitative immunochemical measure of the primary interaction between I* BSA and antibody. J. Infect. Dis. 103:1958;239-262.
23. Plotkin S.A. Immunologic correlates of protection induced by vaccination. Pediatr. Infect. Dis. J. 20:2001;63-75.
24. Grimprel E., Bégué P., Anjak I., Njamkepo E., François P., Guiso N. Long-term human serum antibody responses after immunisation with whole-cell pertussis vaccine in France. Clin. Diagn. Lab. Immunol. 3:1996;93-97.
25. Ausiello C.M., Lande R., Urbani F., Carlo B., Stefanelli P., Salmaso S. et al. Cell-mediated immunity and antibody responses to Bordetella pertussis antigens in children with a history of pertussis infection and in recipients of an acellular pertussis vaccine. J. Infect. Dis. 181:2000;1989-1995.
26. Grimprel E., Baron S., Lévy-Bruhl D., Garnier J.M., N'jamkepo E., Guiso N.et al. Influence of vaccination coverage on pertussis transmission in France. Lancet. 354:1999;1699-1700.
27. Guiso N, Bégué P, Cohen R, Gaudelus J, Olivier C, Vie le Sage F, et al. Comparison of pertussis antibody levels in children up to 5 years of age primed at 2, 3, 4 months and boostered in the second year of life with either DTPa or DTPw based combination vaccines, in France. In: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, 17-20 September 2000 [Abstract].
28. De Melker H.E., Versteegh F.G.A., Conyn-Van Spaendonck M.A.E., Elvers L.H., Berbers G.A.M., Van der Zee A.et al. J. Clin. Microbiol. 38:2000;800-806.
29. Danjou G, Silier T, Dupuy M. Comparison of DTacP-IPV vaccine with DTP-IPV (TETRACOQ(tm)) vaccine administered as a second booster at 4 to 7 years of age. In: 15th Annual Meeting of European Society for Paediatric Infectious Diseases, Paris, 22-23 May 1997 [Abstract].
30. Tozzi A.E., Anemona A., Stefanelli P., Salmaso S., Ciofi degli Atti M.L., Mastrantonio P.et al. Reactogenicity and immunogenicity at preschool age of a booster dose of two three-component diphtheria-tetanus-acellular pertussis vaccines in children primed in infancy with acellular vaccines. Pediatrics. 107:2001;1-9.
31. Blennow M., Granström M. Adverse reactions and serologic response to a booster dose of acellular pertussis vaccine in children immunized with acellular or whole-cell vaccine as infants. Pediatrics. 84:1989;62-67.